Stanford



Julia D. Ransohoff

Instructor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

900 Blake Wilbur 3rd Fl

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 497-0736

ACADEMIC CONTACT INFORMATION

- **Email**

  Email ransohoff@stanford.edu

Bio

BIO

Dr. Ransohoff received her B.A. from Harvard College in Human Developmental and Regenerative Biology and completed her medical training at Stanford University, where she received her M.D., completed residency in internal medicine, and fellowship training in hematology and oncology as part of the American Board of Internal Medicine Physician Scientist Training Program.

Dr. Ransohoff is a physician-scientist dedicated to improving breast cancer treatments and outcomes through developing genomic methods to profile how tumors respond to treatment. Her research focuses on molecular approaches to understand the variable clinical responses of breast cancers to treatment at the genomic level by profiling molecular residual disease. Her current work involves exploring mechanisms of chemoresistance and immune evasion and identifying novel therapeutic targets. In related work, she also studies epidemiological risk factors for breast cancer mortality with a focus on the gut microbiome, oncofertility, and racial and ethnic differences in treatment response. Dr. Ransohoff's research has been supported by the ASCO Conquer Cancer Foundation, the Terri Brodeur Breast Cancer Foundation, the Stanford Cancer Institute, ECOG-ACRIN, and the Chan Zuckerberg Initiative.

As an Instructor in the Division of Medical Oncology, Dr. Ransohoff is also a clinically active oncologist, treating patients with breast cancer.

CLINICAL FOCUS

- Breast Oncology
- Medical Oncology
- Oncology

ACADEMIC APPOINTMENTS

- Instructor, Medicine - Oncology

HONORS AND AWARDS

- Fellowship Award, Stanford Cancer Institute (2025)
- Young Investigator Award, ASCO Conquer Cancer Foundation (2025)

- Terri Brodeur Breast Cancer Foundation Award, Terri Brodeur Breast Cancer Foundation (2024-2026)
- Early Investigator Award, San Antonio Breast Cancer Symposium (2024)
- Chan Zuckerberg Physician-Scientist Fellowship Award, Chan Zuckerberg Initiative (2023-2025)
- Clinical Scholar Award, San Antonio Breast Cancer Symposium (2023)
- Paul Carbone, MD Fellowship Award, ECOG-ACRIN (2023)
- Translational Research and Applied Medicine Scholar, Stanford University (2022-2025)
- Chief Fellow, Stanford Hematology and Oncology Fellowship, Stanford University (2022 – 2023)
- Physician Scientist Training Program, Stanford Department of Medicine Translational Investigator Program (2018-2020)
- Howard Hughes Medical Investigators Medical Research Fellow, Howard Hughes Foundation (2016-2017)
- Gold Humanism Honor Society, The Arnold P. Gold Foundation (2016)
- John Harvard Scholar, Harvard College (2009)
- National Finalist, Intel Science Talent Search (2009)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2025) CA
- Board Certification: Oncology, American Board of Internal Medicine (2024)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2021)
- Residency: Stanford University Internal Medicine Residency (2020) CA
- Medical Education: Stanford University Medical School (2018) CA
- Board Certification, American Board of Internal Medicine , Medical Oncology (2024)
- Board Certification, American Board of Internal Medicine , Internal Medicine (2021)
- Fellowship, Stanford University , Hematology and Oncology (2025)
- Residency, Stanford University , Internal Medicine (2020)
- MD, Stanford University (2018)
- BA, Harvard University , Human Developmental and Regenerative Biology (2012)

Publications

PUBLICATIONS

- **Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer.** *JAMA oncology*
  Ransohoff, J. D., Lewinsohn, R. M., Dickerson, J., Luo, I., Satoyoshi, M., Ritter, V., Chavez, R., Wheeler, A. J., Liang, S. Y., Kenkare, P., Gomez, S. L., Schapira, L., John, et al
  2025

- **Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer family registry.** *JNCI cancer spectrum*
  Ransohoff, J. D., Miller, I., Koo, J., Joshi, V., Kurian, A. W., Allison, K. H., John, E. M., Telli, M. L.
  2024

- **Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer.** *Nature communications*
  Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S., Liu, M., Liang, S. Y., John, E. M., Gomez, S. L., Telli, M. L., Schapira, L., Itakura, H., Sledge, et al
  2023; 14 (1): 2053

- **Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning.** *JAMA oncology*
  Ransohoff, J. D., Nikfarjam, A. n., Jones, E. n., Loew, B. n., Kwong, B. Y., Sarin, K. Y., Shah, N. H.
  2018; 4 (4): 581–83

- **The functions and unique features of long intergenic non-coding RNA.** *Nature reviews. Molecular cell biology*
  Ransohoff, J. D., Wei, Y. n., Khavari, P. A.
  2018; 19 (3): 143–57
- **Assessment of Accuracy of Patient-Initiated Differential Diagnosis Generation by Google Reverse Image Searching.** *JAMA dermatology*
  Ransohoff, J. D., Li, S., Sarin, K. Y.
  2016; 152 (10): 1164-1166
- **Referred by Google: mining Trends data to identify patterns in and correlates to searches for dermatologic concerns and providers.** *The British journal of dermatology*
  Ransohoff, J. D., Sarin, K. Y.
  2017
- **Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.** *Clinical lymphoma, myeloma & leukemia*
  Ransohoff, J. D., Kwong, B. Y.
  2017; 17 (12): 834–51
- **Health Cards by Google: dermatologist review of inclusivity and utility of the medical search application.** *British journal of dermatology*
  Ransohoff, J. D., Sarin, K. Y.
  2016
- **CALML5 is a ZNF750-and TINCR-induced protein that binds stratifin to regulate epidermal differentiation** *GENES & DEVELOPMENT*
  Sun, B. K., Boxer, L. D., Ransohoff, J. D., Siprashvili, Z., Qu, K., Lopez-Pajares, V., Hollmig, S. T., Khavari, P. A.
  2015; 29 (21): 2225-2230
- **Tracking gene and cell fate for therapeutic gain** *Nature Materials*
  Kooreman*, N. G., Ransohoff*, J. D., Wu, J. C., (*co-first authors)
  2014; 13: 106-109
- **Immunogenicity of Pluripotent Stem Cells and Their Derivatives** *CIRCULATION RESEARCH*
  de Almeida, P. E., Ransohoff, J. D., Nahid, A., Wu, J. C.
  2013; 112 (3): 549-561
- **Costimulation-Adhesion Blockade is Superior to Cyclosporine A and Prednisone Immunosuppressive Therapy for Preventing Rejection of Differentiated Human Embryonic Stem Cells Following Transplantation** *Stem Cells*
  Huber*, B. C., Ransohoff*, J. D., Ransohoff, K. J., Riegler, J., Ebert, A., Kodo, K., Gong, Y., Sanchez-Freire, V., Dey, D., Kooreman, N. G., Diecke, S., Zhang, W. Y., Odegaard, et al
  2013; 11: 2354-63
- **Imaging Stem Cell Therapy for the Treatment of Peripheral Arterial Disease** *CURRENT VASCULAR PHARMACOLOGY*
  Ransohoff, J. D., Wu, J. C.
  2012; 10 (3): 361-373
- **In Vivo Functional and Transcriptional Profiling of Bone Marrow Stem Cells After Transplantation Into Ischemic Myocardium** *ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY*
  Sheikh, A. Y., Huber, B. C., Narsinh, K. H., Spin, J. M., van der Bogt, K., de Almeida, P. E., Ransohoff, K. J., Kraft, D. L., Fajardo, G., Ardigo, D., Ransohoff, J., Bernstein, D., Fischbein, et al
  2012; 32 (1): 92-102
- **Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells** *CELL STEM CELL*
  Pearl, J. I., Lee, A. S., Leveson-Gower, D. B., Sun, N., Ghosh, Z., Lan, F., Ransohoff, J., Negrin, R. S., Davis, M. M., Wu, J. C.
  2011; 8 (3): 309-317